|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mesenteric Venous Thrombosis显示文摘 | Ashwani K. Singal Patrick S. Kamath Ayalew Tefferi | 2013 | Mayo Clinic Proceedings2013，，3： | 3 |
| 2 | 关于修订WHO真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断标准的建议和说明:来自特别国际专家组的推荐显示文摘最近对BCR-ABL阴性骨髓增殖性疾病(MPDs)分子发病机制的新发现为这类疾病的遗传学分类及分子诊断带来了希望。相关报道最早发表在2005年初,这些文献描述了真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)患者存在体细胞Janus激酶2(JAK2)的突变(JAK2617V〉F;一种外显子14体细胞1849G〉T突变);在PV患者中突变率约95%,ET和PMF均约50%。 | Tefferi A Thiele J Orazi A 蓝海峰(译) 杨仁池(校) | 2007 | 国际输血及血液学杂志2007，30，6： | 2 |
| 3 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFR-α, PDGFR-β and FGFR1 显示文摘 | Tefferi A | 2009 | J Cell Mol Med2009，13，2： | 1 |
| 4 | Late - onset noninfectiouspulmonary complications after allogeneic bone marrow transplanta- tion 显示文摘 | Palmas A Tefferi A Myers JL | 1998 | Br J Haemotol1998，100，4： | 1 |
| 5 | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival:clinical evidence for leukemogenic collaboration with JAK-2 V617F显示文摘 | Tefferi A Jimma T Sulai NH | | 0，，03： | 1 |
| 6 | Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagaaostic algorithms 显示文摘 | Tefferi A Vardiman JW | 2008 | Leukemia2008，22，1： | 1 |
| 7 | Polycythemia vera and essential thrombocythemia : 2015 update on diagnosis, risk-stratification and management 显示文摘 | Tefferi A Barbui T | 2015 | Am J Hematol2015，90，2： | 1 |
| 8 | Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera essential thrombocythemia and primary myelofibrosis recommendations from an ad hoe international expert panel 显示文摘 | Tefferi A Thiele J Orazi A | 2007 | Blood2007，110，4： | 1 |
| 9 | An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms 显示文摘 | Tefferi A Thiele J Vannucchi AM | 2014 | Leukemia2014，28，7： | 1 |
| 10 | Essential thrombocythemia,polycythemia vera, and myelofibrosis:current management and the prospect of targe- ted therapy 显示文摘 | Tefferi A | 2008 | Am J Hemato12008，83，6： | 1 |
| 11 | Cellular distribution of plateletderived growth factor, trans-forming growth 显示文摘 | Yoon SY Tefferi A Li CY | 2000 | Acta Haematol2000，104，4： | 1 |
| 12 | Personalized management of essential throm- bocythemia-application of recent evidence to clinical practice 显示文摘 | Tefferi A Barbui T | 2013 | Leukemia2013，27，8： | 1 |
| 13 | Calreticulin mutations and long-term survival in essential thmmboeythemia 显示文摘 | Tefferi A Wassie EA Lasho TL | 2014 | Leukemia2014，28，12： | 1 |
| 14 | polycythemia vera-associated acquired yon willebrand syndrome despite near-normal platelet count 显示文摘 | Tefferi A Smock KJ Divgi AB | 2010 | Am J Hematol2010，85，7： | 1 |
| 15 | Classification and diagnosis of myelopmliferative neoplasms according to the 2008 World Health Organization criteria显示文摘 | Wadleigh M Tefferi A | 2010 | Int J Hematol2010，91，2： | 1 |
| 16 | The interaction between leuko- cytosis and other risk factors for thrombosis in essential thrombo- cythemia显示文摘 | Tefferi A Gangat N Wolanskyj A | 2007 | Blood2007，109，9： | 1 |
| 17 | TET2 mutations and their clinical correlates in polyeythemia vera, essential thrombocythemia and myelofibrosis显示文摘 | Tefferi A Pardanani A Lim KH | 2009 | Leukemia2009，23，5： | 1 |
| 18 | The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia; lineage specificity and clinical correlates 显示文摘 | TEFFERI A LASHO T L SCHWAGER S M | 2005 | Br J Haematol2005，131，3： | 1 |
| 19 | Bronchiolitis obliterans and other late onset non - infectious pulmonary complications in hcmatopoiet- ic stem cell transplantation 显示文摘 | Afessa B Litzow MR Tefferi A | 2001 | Bone Marrow Transplant2001，28，5： | 1 |
| 20 | Validation and comparison of contemporary prognostic models in primary myelofibrosis:analysis based on 334 patients from a single institution显示文摘 | Tefferi A Huang J Schwager S | 2007 | Cancer2007，109，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员